01 September 2005
Gelstat Migraine((R)) (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase.Roger K. Cady, Curtis P. Schreiber, Mary E. Beach, Carolyn C. Hart
Med Sci Monit 2005; 11(9): PI65-69 :: ID: 428456
Background: Treatment of migraine headaches is often delayed due to assessingthe potential severity of an evolving headache or anticipating unwanted consequences from prescriptionmedication. Studies have demonstrated improved pain-free response when prescription treatments are takenduring the mild headache phase of a migraine. This study was designed to evaluate the efficacy of anOTC product, GelStat Migraine((R)), when taken in the early, mild pain phase of migraine. Material/Methods:An open-label study enrolling 30 subjects, male and female, with a one-year history of migraine meetingIHS diagnostic criteria with or without aura, 2-8 migraines per month and 15 headache days per month.Inclusion required having migraines that consistently started at mild and worsened to moderate or severe,if untreated, in at least 75% of attacks. Subjects also had to be able to distinguish migraine from non-migraineheadaches and reliably identify migraine early in the course of an attack. One headache was treated inthe mild pain phase with GelStat Migraine((R)), a combination of feverfew and ginger. Results: 29 evaluablesubjects completed the study, all treating at mild pain. Two hours after treatment, 48% were pain-freewith 34% reporting a headache of only mild severity. 29% reported a recurrence within 24 hours. Sideeffects were minimal and not serious. 59% of subjects were satisfied with Gelstat Migraine((R)) therapyand 41% preferred GelStat Migraine((R)) or felt it was equal to their pre-study medication. Conclusions:GelStat Migraine((R)) is effective as a first line abortive treatment for migraine when initiated earlyduring the mild headache phase.
Keywords: Administration, Sublingual, Analgesics - therapeutic use, Ginger, Migraine Disorders - physiopathology, Nonprescription Drugs, Pain - physiopathology, Phytotherapy, Tanacetum parthenium
01 February 2023 : EditorialEditorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread
Med Sci Monit 2023; 29:e939580
19 January 2023 : Clinical ResearchEvaluation of Health-Related Quality of Life and Mental Health in 729 Medical Students in Indonesia During ...
Med Sci Monit In Press; DOI: 10.12659/MSM.938892
19 January 2023 : Clinical ResearchDetermining the Impact of the COVID-19 Pandemic on Dental Care in the Serbian Adult Population: An Online Q...
Med Sci Monit 2023; 29:e939238
27 December 2022 : Clinical ResearchEffect of Physiotherapy to Correct Rounded Shoulder Posture in 30 Patients During the COVID-19 Pandemic in ...
Med Sci Monit 2022; 28:e938926
03 Feb 2023 : Clinical ResearchTreatment of Gingival Recession Defects with Pouch and Tunnel Technique Using Connective Tissue Graft and L...
Med Sci Monit In Press; DOI: 10.12659/MSM.938865
02 Feb 2023 : Clinical ResearchOnline Questionnaire-Based Study to Evaluate the Attitudes and Use of Rubber Dental Dams by Saudi Dental Pr...
Med Sci Monit In Press; DOI: 10.12659/MSM.938672
02 Feb 2023 : Database AnalysisPrognostic-Related Biomarkers in Pancreatic Ductal Adenocarcinoma Correlating with Immune Infiltrates Based...
Med Sci Monit In Press; DOI: 10.12659/MSM.938785
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292